Wuxi Cathy Pharmaceuticals

Wuxi Cathy Pharmaceuticals is a Chinese pharmaceutical company based in Wuxi, specializing in the development and manufacturing of treatments for central nervous system (CNS) and geriatric conditions. Established in 2002, the company operates as a subsidiary of Guanying Development and maintains GMP-certified facilities for the production of oral solid dosage forms, including hard capsules and tablets. Its primary commercial product is Aniracetam, a nootropic agent and AMPA receptor modulator used to treat memory impairment and cognitive decline in elderly patients and those with cerebrovascular diseases. The company also participates in clinical research for other neuroprotective agents, such as Oxiracetam, and explores combination therapies for acute cerebral infarction. Wuxi Cathy Pharmaceuticals is distinct from the Italian multinational Chiesi, despite sharing the same Chinese name "凯西".